In the bio-tech market, U.S. Bancorp's activity is noteworthy. Shareholders are to receive larger dividends than the previous year, along with the company's announcement of a $5 billion common stock repurchase program. Insiders have recently sold US$1.9m of stock, which could suggest caution. Additionally, Envestnet Asset Management has $319.13 Million stock holdings in U.S. Bancorp. Royal Bank of Canada has given the firm an 'Outperform' rating. U.S. Bancorp has shown positive results with Q2 Earnings and Revenues topping estimates and neutral ratings being maintained based on financial outlook. There has been significant activity regarding the U.S. Bancorp stock, with some insiders buying and others, such as Federated Hermes Inc., lowering their positions. Notably, U.S. Bancorp units have announced partnerships with Edward Jones, with Arijit Roy being appointed to the U.S. Bank Managing Committee and Director Aleem Gillani purchasing 10,000 shares. In relation to stock performance, despite reporting lower adjusted earnings and revenue drops in Q2, U.S. Bancorp's stock is still considered cheap.
US Bancorp USB News Analytics from Fri, 16 Feb 2024 21:30:19 GMT to Sun, 15 Sep 2024 13:12:59 GMT - Rating 8 - Innovation 6 - Information 7 - Rumor -2
